Drugs / Osteodex
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06616389 | Nov 2023 → Jan 2026 overdue | plasma cell myeloma | DexTech Medical AB | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Osteodex | “ODX (Osteodex)” NCT06616389 ↗ |
| Known as | ODX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06616389 ↗ |